摘要
对于HR^(+)/HER-2^(-)乳腺癌患者来说,内分泌治疗扮演着非常重要的角色。长久以来,医学工作者对于此类患者的内分泌耐药机制以及相关治疗方法的讨论也层出不穷。近年来,CDK4/6抑制剂为HR^(+)患者的带来了福音,CDK4/6抑制剂单药治疗与联合内分泌治疗已经用于晚期乳腺癌的治疗。除了内分泌治疗之外,CDK4/6抑制剂还可以与抗HER-2药物、PD-L1、PD-L1抑制剂或其他靶向药物联合,联合治疗在一定程度上克服了CDK4/6抑制剂的耐药情况,并提高了治疗疗效,为乳腺癌患者的精准治疗带来了福音。
Endocrine therapy plays a very important role for HR^(+)/HER-2^(-)breast cancer patients.For a long time,medical workers have been discussing the mechanism of endocrine resistance and related treatment methods in such patients.In recent years,CDK4/6 inhibitors have been a boon for HR patients,with CDK4/6 inhibitors monotherapy combined with endocrine therapy being used in the treatment of advanced breast cancer.In addition to endocrine therapy,CDK4/6 inhibitors can also be combined with anti-HER-2 drugs,PD-L1,PD-L1 inhibitors,or other targeted drugs.Combined therapy overcomes the resistance of CDK4/6 inhibitors to a certain extent,improves the efficacy,and brings good news to the precision treatment of breast cancer patients.
作者
常春
王静萱
CHANG Chun;WANG Jingxuan(Department of Oncology,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,China)
出处
《现代肿瘤医学》
CAS
北大核心
2021年第17期3120-3124,共5页
Journal of Modern Oncology
基金
国家自然科学基金项目(编号:81772813)。
